Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis

Cellular Oncology

Volumn 38, Issue 2, 2015, Pages 93-109

  Shahjahani, Mohammad ^a   Mohammadiasl, Javad ^b   Noroozi, Fatemeh ^b   Seghatoleslami, Mohammad ^b   Shahrabi, Saeid ^c   Saba, Fakhredin ^a   Saki, Najmaldin ^b  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SEMNAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CLL; Cytogenetic abnormality; Epigenetic alteration; Micro RNA; Signaling pathways; Somatic mutation

Indexed keywords

GENETICS; HUMAN; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MORTALITY; PROGNOSIS;

HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROGNOSIS;

EID: 84939963271     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-014-0215-3     Document Type: Review

References (178)

1. F. Talab, J.C. Allen, V. Thompson, K. Lin, J.R. Slupsky, LCK is an important mediator of B-cell receptor signaling in chronic lymphocytic leukemia cells. Mol. Cancer Res. 11, 541–554 (2013)
2. T. Robak, Inhibitors of B-Cell receptor signaling for the treatment of chronic lymphocytic leukemia. J. Leuk. 1, 101 (2013)
3. G. Dighiero, T. Hamblin, Chronic lymphocytic leukaemia. Lancet 371, 1017–1029 (2008)
4. C. Rozman, E. Montserrat, Chronic lymphocytic leukemia. N. Engl. J. Med. 333, 1052–1057 (1995)
5. J.A. Zwiebel and B.D. Semin. Oncol. 42–59 (1998).
6. S.E. Herman, A.L. Gordon, A.J. Wagner, N.A. Heerema, W. Zhao, J.M. Flynn, J. Jones, L. Andritsos, K.D. Puri, B.J. Lannutti, Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116, 2078–2088 (2010)
7. E. Matutes, R. Morilla, K. Owusu-Ankomah, A. Houlihan, D. Catovsky, The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood 83, 1558–1562 (1994)
8. E. Matutes, K. Owusu-Ankomah, R. Morilla, M.J. Garcia, A. Houlihan, T. Que, D. Catovsky, The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8, 1640–1645 (1994)
9. R.E. Shackelford, A.R. Bhalodia, J.D. Cotelingam, D.M. Veillon, M. Lowery-Nordberg, Increased transferrin receptor expression following 11q23 deletion as a mechanism of malignant progression in chronic lymphocytic leukemia. Med. Hypotheses 66, 509–512 (2006)
10. S. Willimott, D. Beck, M.J. Ahearne, V.C. Adams, S.D. Wagner, Cap-translation inhibitor, 4EGI-1, restores sensitivity to ABT-737 apoptosis through cap-dependent and-independent mechanisms in chronic lymphocytic leukemia. Clin. Cancer Res. 19, 3212–3223 (2013)
11. J. Chen, N.A. McMillan, Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia. Cancer Biol. Ther. 7, 174 (2008)
12. A.E. Rodríguez-Vicente, M.G. Díaz, J.M. Hernandez-Rivas, Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. Cancer Genet. 206, 49–62 (2013)
13. Y. Pekarsky, N. Zanesi, C.M. Croce, Molecular basis of CLL. Semin. Cancer Biol. 20, 370–376 (2010)
14. N. Chiorazzi, K.R. Rai, M. Ferrarini, Chronic lymphocytic leukemia. N. Engl. J. Med. 352, 804–815 (2005)
15. M.L. Palomba, K. Piersanti, C.G. Ziegler, H. Decker, J.W. Cotari, K. Bantilan, I. Rijo, J.R. Gardner, M. Heaney, D. Bemis, Multidimensional single-cell analysis of BCR signaling reveals proximal activation defect as a hallmark of chronic lymphocytic leukemia B cells. PLoS One 9, e79987 (2014)
16. S. Stilgenbauer, T. Zenz, Genetics in chronic lymphocytic leukemia. Leukemia 16, 993–1007 (2002)
17. D. Mertens, S. Stilgenbauer, Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches? J. Clin. Oncol. 32, 869–872 (2014)
18. J. Ma, C. Dong, C. Ji, MicroRNA and drug resistance. Cancer Gene Ther. 17, 523–531 (2010)
19. R. Rosenquist, D. Cortese, S. Bhoi, L. Mansouri, R. Gunnarsson, Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand? Leuk. Lymphoma 54, 2351–2364 (2013)
20. E. San Jose-Eneriz, X. Agirre, P. Rodríguez-Otero, F. Prosper, Epigenetic regulation of cell signaling pathways in acute lymphoblastic leukemia. Epigenomics. 5, 525–538 (2013)
21. L. Mansouri, N. Cahill, R. Gunnarsson, K.E. Smedby, E. Tjönnfjord, H. Hjalgrim, G. Juliusson, C. Geisler, R. Rosenquist, NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia. Leukemia 27, 512–514 (2012)
22. L. Mansouri, P. Grabowski, S. Degerman, U. Svenson, R. Gunnarsson, N. Cahill, K.E. Smedby, C. Geisler, G. Juliusson, G. Roos, Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients. Am. J. Hematol. 88, 647–651 (2013)
23. D. Rossi, S. Rasi, V. Spina, A. Bruscaggin, S. Monti, C. Ciardullo, C. Deambrogi, H. Khiabanian, R. Serra, F. Bertoni, Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 121, 1403–1412 (2013)
24. J.A. Burger, Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Curr. Hematol. Malig. Rep. 7, 26–33 (2012)
25. G. Gaidano, R. Foà, R. Dalla-Favera, Molecular pathogenesis of chronic lymphocytic leukemia. J. Clin. Invest. 122, 3432–3438 (2012)
26. M. Hallek, Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am. J. Hematol. 88, 803–816 (2013)
27. E. Tausch, D. Mertens, S. Stilgenbauer, Advances in treating chronic lymphocytic leukemia. F1000Prime Rep. 6, 65 (2014)
28. R. Foà, I. Del Giudice, A. Guarini, D. Rossi, G. Gaidano, Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica 98, 675–685 (2013)
29. P.C. Monroig, G.A. Calin, MicroRNA and epigenetics: diagnostic and therapeutic opportunities. Curr. Pathobiol. Rep. 1, 43–52 (2013)
30. L.R. Corsini, G. Bronte, M. Terrasi, V. Amodeo, D. Fanale, E. Fiorentino, G. Cicero, V. Bazan, A. Russo, The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin. Ther. Targets 16, S103–S109 (2012)
31. P. Li, X. Wang, Role of signaling pathways and miRNAs in chronic lymphocytic leukemia. Chin. Med. J. (Engl.) 126, 4175–4182 (2013)
32. L.P. Frenzel, R. Claus, N. Plume, J. Schwamb, C. Konermann, C.P. Pallasch, J. Claasen, R. Brinker, B. Wollnik, C. Plass, Sustained NF‐kappaB activity in chronic lymphocytic leukemia is independent of genetic and epigenetic alterations in the TNFAIP3 (A20) locus. Int. J. Cancer 128, 2495–2500 (2011)
33. R. Horie, M. Watanabe, T. Okamura, M. Taira, M. Shoda, T. Motoji, A. Utsunomiya, T. Watanabe, M. Higashihara, K. Umezawa, DHMEQ, a new NF-κB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells. Leukemia 20, 800–806 (2006)
34. L. Coll-Mulet, D. Iglesias-Serret, A.F. Santidrián, A.M. Cosialls, M. de Frias, E. Castaño, C. Campàs, M. Barragán, A.F. de Sevilla, A. Domingo, MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 107, 4109–4114 (2006)
35. K. Kojima, M. Konopleva, T. McQueen, S. O’Brien, W. Plunkett, M. Andreeff, Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 108, 993–1000 (2006)
36. D.A. Carney, W.G. Wierda, Genetics and molecular biology of chronic lymphocytic leukemia. Curr. Treat Options Oncol. 6, 215–225 (2005)
37. C. Haferlach, F. Dicker, S. Schnittger, W. Kern, T. Haferlach, Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH. IgVH status and immunophenotyping. Leukemia 21, 2442–2451 (2007)
38. D. Pfeifer, M. Pantic, I. Skatulla, J. Rawluk, C. Kreutz, U.M. Martens, P. Fisch, J. Timmer, H. Veelken, Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 109, 1202–1210 (2007)
39. J.Y. Hehir-Kwa, M. Egmont-Petersen, I.M. Janssen, D. Smeets, A. Geurts van Kessel, J.A. Veltman, Genome-wide copy number profiling on high-density bacterial artificial chromosomes, single-nucleotide polymorphisms, and oligonucleotide microarrays: a platform comparison based on statistical power analysis. DNA Res. 14, 1–11 (2007)
40. C. Meldrum, M.A. Doyle, R.W. Tothill, Next-generation sequencing for cancer diagnostics: a practical perspective. Clin. Biochem. Rev. 32, 177 (2011)
41. G. Fabbri, S. Rasi, D. Rossi, V. Trifonov, H. Khiabanian, J. Ma, A. Grunn, M. Fangazio, D. Capello, S. Monti, Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J. Exp. Med. 208, 1389–1401 (2011)
42. L. Wang, M.S. Lawrence, Y. Wan, P. Stojanov, C. Sougnez, K. Stevenson, L. Werner, A. Sivachenko, D.S. DeLuca, L. Zhang, SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365, 2497–2506 (2011)
43. S. Azizidoost, S. Babashah, F. Rahim, M. Shahjahani, N. Saki, Bone marrow neoplastic niche in leukemia. Hematology 19, 232–238 (2014)
44. J.A. Burger, J.G. Gribben, Semin. Cancer Biol. 24, 71–81 (2014)
45. A.N. Kamdje, G. Bassi, L. Pacelli, G. Malpeli, E. Amati, I. Nichele, G. Pizzolo, M. Krampera, Role of stromal cell-mediated notch signaling in CLL resistance to chemotherapy. Blood Cancer J. 2, e73 (2012)
46. F. Saba, M. Soleimani, A. Atashi, E. Mortaz, M. Shahjahani, E. Roshandel, K. Jaseb, N. Saki, The role of the nervous system in hematopoietic stem cell mobilization. Lab. Hematol. 19, 8–16 (2013)
47. A. Wiestner, Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 120, 4684–4691 (2012)
48. N. Saki, S. Abroun, M.F. Hagh, F. Asgharei, Neoplastic bone marrow niche: hematopoietic and mesenchymal stem cells. Cell J. 13, 131 (2011)
49. M.F. de Rooij, A. Kuil, C.R. Geest, E. Eldering, B.Y. Chang, J.J. Buggy, S.T. Pals, M. Spaargaren, The clinically active BTK inhibitor PCI-32765 targets B-cell receptor–and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119, 2590–2594 (2012)
50. J. Hoellenriegel, S.A. Meadows, M. Sivina, W.G. Wierda, H. Kantarjian, M.J. Keating, N. Giese, S. O’Brien, A. Yu, L.L. Miller, The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118, 3603–3612 (2011)
51. S. López-Giral, N.E. Quintana, M. Cabrerizo, M. Alfonso-Pérez, M. Sala-Valdés, V.G.G. de Soria, J.M. Fernández-Rañada, E. Fernández-Ruiz, C. Muñoz, Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J. Leukoc. Biol. 76, 462–471 (2004)
52. J.A. Burger, M. Burger, T.J. Kipps, Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94, 3658–3667 (1999)
53. J. Barretina, J. Junca, A. Llano, A. Gutierrez, A. Flores, J. Blanco, B. Clotet, J. Este, CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease. Ann. Hematol. 82, 500–505 (2003)
54. F. Bennett, A. Rawstron, M. Plummer, R. Tute, P. Moreton, A. Jack, P. Hillmen, B‐cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle. Br. J. Haematol. 139, 600–604 (2007)
55. G. Müller, U.E. Höpken, M. Lipp, The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol. Rev. 195, 117–135 (2003)
56. J.A. Burger, M.P. Quiroga, E. Hartmann, A. Bürkle, W.G. Wierda, M.J. Keating, A. Rosenwald, High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 113, 3050–3058 (2009)
57. A. Shaffer, X. Yu, Y. He, J. Boldrick, E.P. Chan, L.M. Staudt, BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 13, 199–212 (2000)
58. A. Zucchetto, C. Tripodo, D. Benedetti, S. Deaglio, G. Gaidano, G. Del Poeta, V. Gattei, Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38+ CD49d + chronic lymphocytic leukaemia cells. Br. J. Haematol. 150, 111–112 (2010)
59. J.A. Burger, N. Chiorazzi, B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 34, 592–601 (2013)
60. S. Mehdi Hoseini, F. Montazeri, A.M. Froughmand, M. Dehghani, H.R. Ghadimi, Introduction to genetic testing–applications, advantages and disadvantages. Genet 3rd millennium 12, 3544–3563 (2014)
61. G. Juliusson, D.G. Oscier, M. Fitchett, F.M. Ross, G. Stockdill, M.J. Mackie, A.C. Parker, G.L. Castoldi, A. Cuneo, S. Knuutila, Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N. Engl. J. Med. 323, 720–724 (1990)
62. J.J. Yunis, High resolution of human chromosomes. Science 191, 1268–1270 (1976)
63. M. Stevens-Kroef, A. Simons, H. Gorissen, T. Feuth, D.O. Weghuis, A. Buijs, R. Raymakers, A. Geurts van Kessel, Identification of chromosomal abnormalities relevant to prognosis in chronic lymphocytic leukemia using multiplex ligation-dependent probe amplification. Cancer Genet. Cytogenet. 195, 97–104 (2009)
64. N.P. Carter, Methods and strategies for analyzing copy number variation using DNA microarrays. Nat. Genet. 39, S16–S21 (2007)
65. M.J. Stevens-Kroef, E. van den Berg, D. Olde Weghuis, A. Geurts van Kessel, R. Pfundt, M. Linssen-Wiersma, M. Benjamins, T. Dijkhuizen, P.J. Groenen, A. Simons, Identification of prognostic relevant chromosomal abnormalities in chronic lymphocytic leukemia using microarray-based genomic profiling. Mol. Cytogenet. 7, 3 (2014)
66. A.M. Snijders, D. Pinkel, D.G. Albertson, Current status and future prospects of array-based comparative genomic hybridisation. Brief Funct. Genom Proteomic. 2, 37–45 (2003)
67. L.E. Vissers, J.A. Veltman, A. Geurts van Kessel, H.G. Brunner, Identification of disease genes by whole genome CGH arrays. Hum. Mol. Genet. 14, R215–R223 (2005)
68. A. Cuneo, G. Rigolin, R. Bigoni, C. De Angeli, A. Veronese, F. Cavazzini, A. Bardi, M. Roberti, E. Tammiso, P. Agostini, Chronic lymphocytic leukemia with 6q − shows distinct hematological features and intermediate prognosis. Leukemia 18, 476–483 (2003)
69. H. Döhner, S. Stilgenbauer, A. Benner, E. Leupolt, A. Kröber, L. Bullinger, K. Döhner, M. Bentz, P. Lichter, Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1910–1916 (2000)
70. T.S. Elton, H. Selemon, S.M. Elton, N.L. Parinandi, Regulation of the MIR155 host gene in physiological and pathological processes. Gene 532, 1–12 (2013)
71. D. Sampath, C. Liu, K. Vasan, M. Sulda, V.K. Puduvalli, W.G. Wierda, M.J. Keating, Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 119, 1162–1172 (2012)
72. L.Q. Wang, Y.L. Kwong, K.F. Wong, C.S.B. Kho, D.Y. Jin, E. Tse, A. Rosèn, C.S. Chim, Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia. J. Transl. Med. 12, 52 (2014)
73. Y.-y. Lai, X.-j. Huang, Cytogenetic characteristics of B cell chronic lymphocytic leukemia in 275 Chinese patients by fluorescence in situ hybridization: a multicenter study. Chin. Med. J. (Engl) 124, 2417 (2011)
74. U. Rozovski, G.A. Calin, T. Setoyama, L. D’Abundo, D.M. Harris, P. Li, Z. Liu, S. Grgurevic, A. Ferrajoli, S. Faderl, Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol. Cancer 12, 50 (2013)
75. T. Herold, V. Jurinovic, M. Mulaw, T. Seiler, A. Dufour, S. Schneider, P.M. Kakadia, M. Feuring‐Buske, J. Braess, K. Spiekermann, Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22‐23 in chronic lymphocytic leukemia—unexpected expression pattern of the RHO GTPase activator ARHGAP20. Genes Chromosom. Cancer 50, 546–558 (2011)
76. G.A. Calin, M. Ferracin, A. Cimmino, G. Di Leva, M. Shimizu, S.E. Wojcik, M.V. Iorio, R. Visone, N.I. Sever, M. Fabbri, A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353, 1793–1801 (2005)
77. M. Ferracin, B. Zagatti, L. Rizzotto, F. Cavazzini, A. Veronese, M. Ciccone, E. Saccenti, L. Lupini, A. Grilli, C. De Angeli, MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol. Cancer 9, 123 (2010)
78. N. Cahill, R. Rosenquist, Uncovering the DNA methylome in chronic lymphocytic leukemia. Epigenetics 8, 138 (2013)
79. S. Kalachikov, A. Migliazza, E. Cayanis, N. Fracchiolla, M. Bonaldo, L. Lawton, P. Jelenc, X. Ye, X. Qu, M. Chien, Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics 42, 369–377 (1997)
80. S. Stilgenbauer, S. Sander, L. Bullinger, A. Benner, E. Leupolt, D. Winkler, A. Kröber, D. Kienle, P. Lichter, H. Döhner, Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 92, 1242–1245 (2007)
81. J.Á. Hernández, A.E. Rodríguez, M. González, R. Benito, C. Fontanillo, V. Sandoval, M. Romero, G. Martín-Núñez, A.G. de Coca, R. Fisac, A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. Haematologica 94, 364–371 (2009)
82. D.L. Van Dyke, T.D. Shanafelt, T.G. Call, C.S. Zent, S.A. Smoley, K.G. Rabe, S.M. Schwager, J.C. Sonbert, S.L. Slager, N.E. Kay, A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B‐chronic lymphocytic leukaemia. Br. J. Haematol. 148, 544–550 (2010)
83. M. Dal Bo, F.M. Rossi, D. Rossi, C. Deambrogi, F. Bertoni, I. Del Giudice, G. Palumbo, M. Nanni, A. Rinaldi, I. Kwee, 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. Genes Chromosom. Cancer 50, 633–643 (2011)
84. J.R. Brown, Insulin receptor activation in deletion 11q chronic lymphocytic leukemia. Clin. Cancer Res. 17, 2605–2607 (2011)
85. R. Karhu, S. Knuutila, O.P. Kallioniemi, S. Siitonen, R. Aine, L. Vilpo, J. Vilpo, Frequent loss of the 11q14‐24 region in chronic lymphocytic leukemia: a study by comparative genomic hybridization. Genes Chromosom. Cancer 19, 286–290 (1997)
86. S.E. Artandi, L.D. Attardi, Pathways connecting telomeres and p53 in senescence, apoptosis, and cancer. Biochem. Biophys. Res. Commun. 331, 881–890 (2005)
87. M.F. Lavin, Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat. Rev. Mol. Cell Biol. 9, 759–769 (2008)
88. A. Pérez-Perarnau, L. Coll-Mulet, C. Rubio-Patiño, D. Iglesias-Serret, A.M. Cosialls, D.M. González-Gironès, M. de Frias, A.F. de Sevilla, E. de la Banda, G. Pons, Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells. Epigenetics 6, 1228–1235 (2011)
89. D. Rossi, M. Cerri, C. Deambrogi, E. Sozzi, S. Cresta, S. Rasi, L. De Paoli, V. Spina, V. Gattei, D. Capello, The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin. Cancer Res. 15, 995–1004 (2009)
90. P. Hillmen, A.B. Skotnicki, T. Robak, B. Jaksic, A. Dmoszynska, J. Wu, C. Sirard, J. Mayer, Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 25, 5616–5623 (2007)
91. A.R. Pettitt, R. Jackson, S. Carruthers, J. Dodd, S. Dodd, M. Oates, G.G. Johnson, A. Schuh, E. Matutes, C.E. Dearden, Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J. Clin. Oncol. 30, 1647–1655 (2012)
92. M. Bentz, A. Plesch, L. Bullinger, S. Stilgenbauer, G. Ott, H. Konrad Müller‐Hermelink, M. Baudis, T.F. Barth, P. Möller, P. Lichter, t (11; 14)‐positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B‐cell chronic lymphocytic leukemia. Genes Chromosom. Cancer 27, 285–294 (2000)
93. M. Merup, G. Juliusson, X. Wu, M. Jansson, B. Stellan, O. Rasool, E. Röijer, G. Stenman, G. Gahrton, S. Einhorn, Amplification of multiple regions of chromosome 12, including 12q13–15, in chronic lymphocytic leukaemia. Eur. J. Haematol. 58, 174–180 (1997)
94. P. Josefsson, C.H. Geisler, H. Leffers, J.H. Petersen, M.K. Andersen, J. Jurlander, A.M. Buhl, CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. Blood 109, 4973–4979 (2007)
95. C.Y. Ok, R.R. Singh, F. Vega, Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms. Am. J. Pathol. 180, 2–11 (2012)
96. G.V. Hegde, K.J. Peterson, K. Emanuel, A.K. Mittal, A.D. Joshi, J.D. Dickinson, G.J. Kollessery, R.G. Bociek, P. Bierman, J.M. Vose, Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target. Mol. Cancer Res. 6, 1928–1936 (2008)
97. O. Morozova, M.A. Marra, Applications of next-generation sequencing technologies in functional genomics. Genomics 92, 255–264 (2008)
98. R. Ekblom, J. Galindo, Applications of next generation sequencing in molecular ecology of non-model organisms. Heredity (Edinb). 107, 1–15 (2010)
99. D.A. Landau, S.L. Carter, P. Stojanov, A. McKenna, K. Stevenson, M.S. Lawrence, C. Sougnez, C. Stewart, A. Sivachenko, L. Wang, Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714–726 (2013)
100. X.S. Puente, M. Pinyol, V. Quesada, L. Conde, G.R. Ordóñez, N. Villamor, G. Escaramis, P. Jares, S. Beà, M. González-Díaz, Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101–105 (2011)
101. V. Quesada, L. Conde, N. Villamor, G.R. Ordóñez, P. Jares, L. Bassaganyas, A.J. Ramsay, S. Beà, M. Pinyol, A. Martínez-Trillos, Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44, 47–52 (2012)
102. D. Rossi, C. Ciardullo, V. Spina, G. Gaidano, Molecular bases of chronic lymphocytic leukemia in light of new treatments. Immunol. Lett. 155, 51–55 (2013)
103. D.A. Landau, C.J. Wu, Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Med. 5, 47 (2013)
104. D. Rossi, M. Fangazio, S. Rasi, T. Vaisitti, S. Monti, S. Cresta, S. Chiaretti, I. Del Giudice, G. Fabbri, A. Bruscaggin, Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 119, 2854–2862 (2012)
105. S. Vallabhapurapu, M. Karin, Regulation and function of NF-κB transcription factors in the immune system. Annu. Rev. Immunol. 27, 693–733 (2009)
106. A. Martínez-Trillos, M. Pinyol, A. Navarro, M. Aymerich, P. Jares, M. Juan, M. Rozman, D. Colomer, J. Delgado, E. Giné, Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood 123, 3790–3796 (2014)
107. S.-C. Lin, Y.-C. Lo, H. Wu, Helical assembly in the MyD88–IRAK4–IRAK2 complex in TLR/IL-1R signalling. Nature 465, 885–890 (2010)
108. D.G. Efremov, A. Wiestner, L. Laurenti, Novel agents and emerging strategies for targeting the B-cell receptor pathway in CLL. Mediterr. J. Hematol. Infect. Dis. 4, e2012067 (2012)
109. A.K. Ghosh, N.E. Kay, Critical signal transduction pathways in CLL. Adv. Exp. Med. Biol. 792, 215–239 (2013)
110. A. Rosén, F. Murray, C. Evaldsson, R. Rosenquist, Antigens in chronic lymphocytic leukemia--implications for cell origin and leukemogenesis. Semin. Cancer Biol. 20, 400–409 (2010)
111. F.K. Stevenson, S. Krysov, A.J. Davies, A.J. Steele, G. Packham, B-cell receptor signaling in chronic lymphocytic leukemia. Blood 118, 4313–4320 (2011)
112. R.N. Damle, T. Wasil, F. Fais, F. Ghiotto, A. Valetto, S.L. Allen, A. Buchbinder, D. Budman, K. Dittmar, J. Kolitz, Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia presented in part at the 40th annual meeting of The American Society of Hematology, held in Miami Beach, FL, December 4–8, 1998. Blood 94, 1840–1847 (1999)
113. T.J. Hamblin, Z. Davis, A. Gardiner, D.G. Oscier, F.K. Stevenson, Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848–1854 (1999)
114. R. Wickremasinghe, A. Prentice, A. Steele, p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies. Leukemia 25, 1400–1407 (2011)
115. C.S. Tam, T.D. Shanafelt, W.G. Wierda, L.V. Abruzzo, D.L. Van Dyke, S. O’Brien, A. Ferrajoli, S.A. Lerner, A. Lynn, N.E. Kay, De novo deletion 17p13. 1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the MD Anderson and Mayo Clinic experience. Blood 114, 957–964 (2009)
116. I. Cordone, S. Masi, F.R. Mauro, S. Soddu, O. Morsilli, T. Valentini, M.L. Vegna, C. Guglielmi, F. Mancini, S. Giuliacci, p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 91, 4342–4349 (1998)
117. T. Sperka, J. Wang, K.L. Rudolph, DNA damage checkpoints in stem cells, ageing and cancer. Nat. Rev. Mol. Cell Biol. 13, 579–590 (2012)
118. P. Ouillette, J. Li, R. Shaknovich, Y. Li, A. Melnick, K. Shedden, S.N. Malek, Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. Genes Chromosom. Cancer 51, 1125–1132 (2012)
119. B. Austen, J.E. Powell, A. Alvi, I. Edwards, L. Hooper, J. Starczynski, A.M.R. Taylor, C. Fegan, P. Moss, T. Stankovic, Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 106, 3175–3182 (2005)
120. B. Austen, A. Skowronska, C. Baker, J.E. Powell, A. Gardiner, D. Oscier, A. Majid, M. Dyer, R. Siebert, A.M. Taylor, Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J. Clin. Oncol. 25, 5448–5457 (2007)
121. D. Rossi, G. Gaidano, ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter. Haematologica 97, 5–8 (2012)
122. A. Guarini, M. Marinelli, S. Tavolaro, E. Bellacchio, M. Magliozzi, S. Chiaretti, M.S. De Propris, N. Peragine, S. Santangelo and F. Paoloni, ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica. 2011.049270 (2011)
123. M.J. Rose-Zerilli, J. Forster, H. Parker, A. Parker, A.E. Rodríguez, T. Chaplin, A. Gardiner, A.J. Steele, A. Collins and B.D. Young, ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia, data from the UK LRF CLL4 trial. Haematologica. 2013.098574 (2014)
124. C. Lobry, P. Oh, I. Aifantis, Oncogenic and tumor suppressor functions of Notch in cancer: it’s NOTCH what you think. J. Exp. Med. 208, 1931–1935 (2011)
125. J.S. Yuan, P.C. Kousis, S. Suliman, I. Visan, C.J. Guidos, Functions of notch signaling in the immune system: consensus and controversies. Annu. Rev. Immunol. 28, 343–365 (2009)
126. K.G. Leong, A. Karsan, Recent insights into the role of Notch signaling in tumorigenesis. Blood 107, 2223–2233 (2006)
127. P. Sportoletti, S. Baldoni, L. Cavalli, B. Del Papa, E. Bonifacio, R. Ciurnelli, A.S. Bell, A. Di Tommaso, E. Rosati, B. Crescenzi, NOTCH1 PEST domain mutation is an adverse prognostic factor in B‐CLL. Br. J. Haematol. 151, 404–406 (2010)
128. D. Rossi, S. Rasi, G. Fabbri, V. Spina, M. Fangazio, F. Forconi, R. Marasca, L. Laurenti, A. Bruscaggin, M. Cerri, Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 119, 521–529 (2012)
129. A. Ahmadzadeh, S. Saedi, K. Jaseb, A.A. Asnafi, A. Alghasi, N. Saki, T-cell acute lymphoblastic leukemia with del (7)(q11. 2q22) and aberrant expression of myeloid markers. Int. J. Hematol. Oncol. Stem Cell Res. 7, 40 (2013)
130. V. Balatti, A. Bottoni, A. Palamarchuk, H. Alder, L.Z. Rassenti, T.J. Kipps, Y. Pekarsky, C.M. Croce, NOTCH1 mutations in CLL associated with trisomy 12. Blood 119, 329–331 (2012)
131. I. Del Giudice, D. Rossi, S. Chiaretti, M. Marinelli, S. Tavolaro, S. Gabrielli, L. Laurenti, R. Marasca, S. Rasi and M. Fangazio, NOTCH1 mutations in + 12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of + 12 CLL. Haematologica. 2011.060129 (2011)
132. S. Weissmann, A. Roller, S. Jeromin, M. Hernández, M. Abáigar, J. Hernández-Rivas, V. Grossmann, C. Haferlach, W. Kern, T. Haferlach, Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 27, 2393–2396 (2013)
133. Y. Wan, C.J. Wu, SF3B1 mutations in chronic lymphocytic leukemia. Blood 121, 4627–4634 (2013)
134. X. Liang, E.A. Moseman, M.A. Farrar, V. Bachanova, D.J. Weisdorf, B.R. Blazar, W. Chen, Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood 115, 5041–5052 (2010)
135. E. Bourke, D. Bosisio, J. Golay, N. Polentarutti, A. Mantovani, The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 102, 956–963 (2003)
136. E. Arvaniti, S. Ntoufa, N. Papakonstantinou, T. Touloumenidou, N. Laoutaris, A. Anagnostopoulos, K. Lamnissou, F. Caligaris-Cappio, K. Stamatopoulos, P. Ghia, Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenetic significance in specific subsets of patients. Haematologica 96, 1644–1652 (2011)
137. D.J. Rawlings, M.A. Schwartz, S.W. Jackson, A. Meyer-Bahlburg, Integration of B cell responses through Toll-like receptors and antigen receptors. Nat. Rev. Immunol. 12, 282–294 (2012)
138. V.N. Ngo, R.M. Young, R. Schmitz, S. Jhavar, W. Xiao, K.-H. Lim, H. Kohlhammer, W. Xu, Y. Yang, H. Zhao, Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115–119 (2011)
139. K. Harikrishnan, S. Bassal, C. Tikellis, A. El-Osta, Expression analysis of the epigenetic methyltransferases and methyl-CpG binding protein families in the normal B-cell and B-cell chronic lymphocytic leukemia (CLL). Cancer Biol. Ther. 3, 989–994 (2004)
140. J.A. Dubovsky, D. Wang, J.J. Powers, E. Berchmans, M.A. Smith, K.L. Wright, E.M. Sotomayor, J.A. Pinilla-Ibarz, Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leuk. Res. 35, 394–404 (2011)
141. E. Yiannakopoulou, Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents–implications for cancer treatment and chemoprevention. Cell. Oncol. 37, 167–178 (2014)
142. M. Kulis, S. Heath, M. Bibikova, A.C. Queirós, A. Navarro, G. Clot, A. Martínez-Trillos, G. Castellano, I. Brun-Heath, M. Pinyol, Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat. Genet. 44, 1236–1242 (2012)
143. P. Tsirigotis, V. Pappa, S. Labropoulos, S. Papageorgiou, F. Kontsioti, J. Dervenoulas, E. Papageorgiou, A. Panani, G. Mantzios, T. Economopoulos, Mutational and methylation analysis of the cyclin‐dependent kinase 4 inhibitor (p16INK4A) gene in chronic lymphocytic leukemia. Eur. J. Haematol. 76, 230–236 (2006)
144. S.G. Papageorgiou, S. Lambropoulos, V. Pappa, C. Economopoulou, F. Kontsioti, E. Papageorgiou, P. Tsirigotis, J. Dervenoulas, T. Economopoulos, Hypermethylation of the p15INK4B gene promoter in B‐chronic lymphocytic leukemia. Am. J. Hematol. 82, 824–825 (2007)
145. L. Pei, J.-H. Choi, J. Liu, E.-J. Lee, B. McCarthy, J.M. Wilson, E. Speir, F. Awan, H. Tae, G. Arthur, Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia. Epigenetics. 7, 567 (2012)
146. A.G. Buggins, C.J. Pepper, The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk. Res. 34, 837–842 (2010)
147. S.-S. Chen, M.H. Sherman, E. Hertlein, A.J. Johnson, M.A. Teitell, J.C. Byrd, C. Plass, Epigenetic alterations in a murine model for chronic lymphocytic leukemia. Cell Cycle 8, 3663–3667 (2009)
148. F.B. Rahmatpanah, S. Carstens, S.I. Hooshmand, E.C. Welsh, O. Sjahputera, K.H. Taylor, L.B. Bennett, H. Shi, J.W. Davis, G.L. Arthur, Large-scale analysis of DNA methylation in chronic lymphocytic leukemia. Epigenetics. 1, 39–61 (2009)
149. M. Corcoran, A. Parker, J. Orchard, Z. Davis, M. Wirtz, O.J. Schmitz, D. Oscier, ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica 90, 1078–1088 (2005)
150. R. Claus, D.M. Lucas, S. Stilgenbauer, A.S. Ruppert, L. Yu, M. Zucknick, D. Mertens, A. Bühler, C.C. Oakes, R.A. Larson, Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J. Clin. Oncol. 30, 2483–2491 (2012)
151. S. Babashah, M. Sadeghizadeh, M.R. Tavirani, S. Farivar, M. Soleimani, Aberrant microRNA expression and its implications in the pathogenesis of leukemias. Cell. Oncol. (Dordr). 35, 317–334 (2012)
152. K.Y. Wong, C.C. So, F. Loong, L.P. Chung, W.W.L. Lam, R. Liang, G.K.H. Li, D.-Y. Jin, C.S. Chim, Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One 6, e19027 (2011)
153. L.Q. Wang, Y.L. Kwong, C.S.B. Kho, K.F. Wong, K.Y. Wong, M. Ferracin, G.A. Calin, C.S. Chim, Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia-implications on constitutive activation of NFκB pathway. Mol. Cancer 7, 11 (2013)
154. C. Mercurio, S. Minucci, P.G. Pelicci, Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol. Res. 62, 18–34 (2010)
155. S.M.A.H. Rad, M.S. Bavarsad, E. Arefian, K. Jaseb, M. Shahjahani, N. Saki, The role of microRNAs in stemness of cancer stem cells. Oncol. Rev. 7, 8 (2013)
156. L. Rask, E. Balslev, R. Sokilde, E. Hogdall, H. Flyger, J. Eriksen, T. Litman, Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status. Cell. Oncol. 37, 215–227 (2014)
157. Y. Wang, M. Li, W. Zang, Y. Ma, N. Wang, P. Li, T. Wang, G. Zhao, MiR-429 up-regulation induces apoptosis and suppresses invasion by targeting Bcl-2 and SP-1 in esophageal carcinoma. Cell. Oncol. 36, 385–394 (2013)
158. A. Veronese, F. Pepe, J. Chiacchia, S. Pagotto, P. Lanuti, S. Veschi, M. Di Marco, A. D’Argenio, I. Innocenti, B. Vannata, Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. Leukemia (2014). doi:10.1038/leu.2014.139
159. S. Srivastava, G.J. Tsongalis, P. Kaur, Recent advances in microRNA-mediated gene regulation in chronic lymphocytic leukemia. Clin. Biochem. 46, 901–908 (2013)
160. S.P. Nana-Sinkam, C.M. Croce, MicroRNA in chronic lymphocytic leukemia: transitioning from laboratory-based investigation to clinical application. Cancer Genet. Cytogenet. 203, 127–133 (2010)
161. U. Klein, R. Dalla-Favera, New insights into the pathogenesis of chronic lymphocytic leukemia. Semin. Cancer Biol. 20, 377–383 (2010)
162. J.L. Mott, S. Kobayashi, S.F. Bronk, G.J. Gores, mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 26, 6133–6140 (2007)
163. Y. Pekarsky, U. Santanam, A. Cimmino, A. Palamarchuk, A. Efanov, V. Maximov, S. Volinia, H. Alder, C.-G. Liu, L. Rassenti, Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 66, 11590–11593 (2006)
164. M. Herling, K. Patel, J. Khalili, E. Schlette, R. Kobayashi, L. Medeiros, D. Jones, TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia 20, 280–285 (2005)
165. M. Mraz, M. Mraz, S. Pospisilova, K. Malinova, I. Slapak, J. Mayer, MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk. Lymphoma 50, 506–509 (2009)
166. T. Zenz, S. Häbe, T. Denzel, J. Mohr, D. Winkler, A. Bühler, A. Sarno, S. Groner, D. Mertens, R. Busch, Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114, 2589–2597 (2009)
167. F. Caligaris-Cappio, Chronic lymphocytic leukemia (CLL): a model for understanding and treating chronic B-cell malignancies. Rinsho Ketsueki. 54, 1838 (2013)
168. R. Visone, L.Z. Rassenti, A. Veronese, C. Taccioli, S. Costinean, B.D. Aguda, S. Volinia, M. Ferracin, J. Palatini, V. Balatti, Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 114, 3872–3879 (2009)
169. S. Rossi, M. Shimizu, E. Barbarotto, M.S. Nicoloso, F. Dimitri, D. Sampath, M. Fabbri, S. Lerner, L.L. Barron, L.Z. Rassenti, microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 116, 945–952 (2010)
170. C. Baer, R. Claus, L.P. Frenzel, M. Zucknick, Y.J. Park, L. Gu, D. Weichenhan, M. Fischer, C.P. Pallasch, E. Herpel, Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. Cancer Res. 72, 3775–3785 (2012)
171. M. Xu, Y.-Y. Mo, The AKT-associated microRNAs. Cell. Mol. Life Sci. 69, 3601–3612 (2012)
172. M.A. Lindsay, microRNAs and the immune response. Trends Immunol. 29, 343–351 (2008)
173. M. Frenquelli, M. Muzio, C. Scielzo, C. Fazi, L. Scarfò, C. Rossi, G. Ferrari, P. Ghia, F. Caligaris-Cappio, MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood 115, 3949–3959 (2010)
174. B. Stamatopoulos, N. Meuleman, B. Haibe-Kains, P. Saussoy, E. Van Den Neste, L. Michaux, P. Heimann, P. Martiat, D. Bron, L. Lagneaux, microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 113, 5237–5245 (2009)
175. K. Zhou, S. Yi, Z. Yu, Z. Li, Y. Wang, D. Zou, J. Qi, Y. Zhao, L. Qiu, MicroRNA-223 expression is uniformly down-regulated in B cell lymphoproliferative disorders and is associated with poor survival in patients with chronic lymphocytic leukemia. Leuk. Lymphoma 53, 1155–1161 (2012)
176. Z. Hua, W. Chun, C. Fang-yuan, MicroRNA-146a and hemopoietic disorders. Int. J. Hematol. 94, 224–229 (2011)
177. J. Redondo-Muñoz, E. Escobar-Díaz, R. Samaniego, M.J. Terol, J.A. García-Marco, Á. García-Pardo, MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by α4β1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 108, 3143–3151 (2006)
178. J. Hayes, P.P. Peruzzi, S. Lawler, MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol. Med. 8, 460–469 (2014)